Fatima Ayub
Researcher
Also affiliated: Tufts Medical Center (2017); Carle Foundation Hospital (2020–2021); King Edward Medical University (2020); Illinois College (2021); Rawalpindi Medical University (2017); Riphah International University (2024); Allama Iqbal Medical College (2020); CMH Lahore Medical College and Institute of Dentistry (2022); University of Arkansas Medical Center (2023–2025); University of Arkansas System (2022); Combined Military Hospital (2018–2020); National University of Medical Sciences (2020–2022)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Fatima Ayub's research focuses on identifying biomarkers for adverse outcomes in patients undergoing cardiac surgery, particularly concerning acute kidney injury. Her work has investigated the predictive value of urinary complement C3 and vitamin D-binding protein for these outcomes. Ayub has also explored various clinical scenarios, including rare drug complications like eptifibatide-induced thrombocytopenia and effective treatments for hypermagnesemia. Her publications also touch upon therapeutic strategies for COVID-19 and patient-centered approaches in dialysis care. Ayub has an h-index of 3, with 27 total publications and 31 citations. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Manisha Singh and Joseph H. Holthoff, and also with Makenzie Kapales at the University of Arkansas at Fayetteville.
Metrics
- h-index: 3
- Publications: 27
- Citations: 31
Selected Publications
-
SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series (2025)
-
Plasma Cell–Directed Rescue With Bortezomib in Refractory Antiphospholipase A2 Receptor–Positive Membranous Nephropathy (2025)
-
Addressing the barriers to peritoneal dialysis—Visual appeal matters (2025)
-
Urinary Complement C3 and Vitamin D-Binding Protein Predict Adverse Outcomes in Patients with Acute Kidney Injury after Cardiac Surgery (2024)
-
I Am the Lucky Third: Spontaneous Resolution of High-Risk Membranous Nephropathy (2023)
-
Triple Jeopardy: Trialled Thrice in the Same Crime (2023)
-
The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor (2023)
-
ANCA-Associated Vasculitis Recurrence After Kidney Transplantation (2023)
-
State Advisory Council: Stakeholders’ Perspective for Shaping the Future of Chronic Kidney Disease Patients in Arkansas (2023)
-
Hemodialysis Is More Effective Than Continuous Venovenous Hemodialysis for Treatment of Hypermagnesemia due to Epsom Salt Ingestion (2022)
-
The Disparities Map: It’s Gone South! (2022)
-
Addressing Barriers to Peritoneal Dialysis: Can It Look Pretty? (2022)
Collaboration Network
Top Collaborators
- Urinary Complement C3 and Vitamin D-Binding Protein Predict Adverse Outcomes in Patients with Acute Kidney Injury after Cardiac Surgery
- Plasma Cell–Directed Rescue With Bortezomib in Refractory Antiphospholipase A2 Receptor–Positive Membranous Nephropathy
- The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor
- I Am the Lucky Third: Spontaneous Resolution of High-Risk Membranous Nephropathy
- Hemodialysis Is More Effective Than Continuous Venovenous Hemodialysis for Treatment of Hypermagnesemia due to Epsom Salt Ingestion
Showing 5 of 6 shared publications
- State Advisory Council: Stakeholders’ Perspective for Shaping the Future of Chronic Kidney Disease Patients in Arkansas
- Addressing Barriers to Peritoneal Dialysis: Can It Look Pretty?
- The Disparities Map: It’s Gone South!
- Addressing the barriers to peritoneal dialysis—Visual appeal matters
- SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series
- The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor
- Triple Jeopardy: Trialled Thrice in the Same Crime
- I Am the Lucky Third: Spontaneous Resolution of High-Risk Membranous Nephropathy
- SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series
- Addressing Barriers to Peritoneal Dialysis: Can It Look Pretty?
- Addressing the barriers to peritoneal dialysis—Visual appeal matters
- Addressing Barriers to Peritoneal Dialysis: Can It Look Pretty?
- Addressing the barriers to peritoneal dialysis—Visual appeal matters
- Triple Jeopardy: Trialled Thrice in the Same Crime
- ANCA-Associated Vasculitis Recurrence After Kidney Transplantation
- I Am the Lucky Third: Spontaneous Resolution of High-Risk Membranous Nephropathy
- ANCA-Associated Vasculitis Recurrence After Kidney Transplantation
- Triple Jeopardy: Trialled Thrice in the Same Crime
- ANCA-Associated Vasculitis Recurrence After Kidney Transplantation
- The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor
- SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series
- The Drug that Keeps Giving: Hypomagnesemia Fixed by SGLT2 Inhibitor
- SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series
- Urinary Complement C3 and Vitamin D-Binding Protein Predict Adverse Outcomes in Patients with Acute Kidney Injury after Cardiac Surgery
- Plasma Cell–Directed Rescue With Bortezomib in Refractory Antiphospholipase A2 Receptor–Positive Membranous Nephropathy
- State Advisory Council: Stakeholders’ Perspective for Shaping the Future of Chronic Kidney Disease Patients in Arkansas
- Addressing Barriers to Peritoneal Dialysis: Can It Look Pretty?
- Addressing Barriers to Peritoneal Dialysis: Can It Look Pretty?
- Addressing Barriers to Peritoneal Dialysis: Can It Look Pretty?
Similar Researchers
Based on overlapping research topics